Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2025

Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2025

 Include: 16 videos + 13 pdfs, size: 4.02 GB

Target Audience: cardiologists, internists, preventive medicine specialists

 Information:

Cardiovascular Atherosclerosis: Prediction, Prevention and Management

May 17, 2025 • San Diego Marriott • La Jolla, California

Conference Overview

Despite notable advances in management, atherosclerotic cardiovascular disease (ASCVD) and its major clinical manifestations remains a leading cause of both morbidity and mortality worldwide.

In the United States alone, ASCVD is the leading cause of death in most racial and ethnic populations and is estimated to cost more than $200 billion per year due to medications, healthcare service utilization, and productivity losses. Many of these human and economic costs are largely attributable to poor implementation of prevention strategies in adults and failure to control ASCVD risk factors using available medications
and lifestyle interventions. The Scripps Cardiovascular Atherosclerosis conference is designed to assist clinicians in the prevention, diagnosis, treatment, and ongoing management of ASCVD among patients in their clinical practices, as well as to promote increased awareness of prudent lifestyle and dietary choices to improve patient outcomes.

Educational Objectives

After attending this live activity, participants should be able to:

• Identify effective treatments, including lifestyle modifications, for managing atherosclerotic cardiovascular disease (ASCVD).
• Evaluate current guideline-directed medical therapy (GDMT) options and emerging strategies for managing cardiovascular disease.
• Identify the unique risk factors, symptoms, and treatment considerations associated with cardiovascular disease in women.
• Describe novel treatment approaches and assess the role of renal denervation in the management of treatment-resistant hypertension.
• Incorporate evidence-based practices in clinical settings for diagnosing, managing, and treating peripheral artery disease.

The Scripps Cardiovascular Atherosclerosis: Prediction, Prevention and Management 2025 symposium is best for cardiologists, internists, preventive medicine specialists, and allied health professionals who want updates on risk assessment, prevention strategies, and management of atherosclerotic cardiovascular disease.

👩‍⚕️ Who Should Attend

• Cardiologists (general and interventional) managing patients with coronary artery disease and vascular risk.
• Internists and family physicians providing frontline preventive care for cardiovascular disease.
• Preventive medicine specialists focusing on risk factor modification and population health.
• Endocrinologists managing diabetes and metabolic syndrome as major contributors to atherosclerosis.
• Nurse practitioners, physician assistants, and pharmacists involved in cardiovascular risk management.
• Residents and fellows in cardiology or internal medicine preparing for board exams or subspecialty practice.

📚 What You’ll Learn

• Risk prediction tools: emerging biomarkers, imaging modalities, and genetic risk assessment.
• Prevention strategies: lifestyle interventions, lipid management, hypertension control, and diabetes care.
• Pharmacologic therapies: statins, PCSK9 inhibitors, anti‑inflammatory agents, and novel drugs.
• Management of established disease: secondary prevention, revascularization, and long‑term outcomes.
• Case‑based discussions: practical approaches to complex patients with multiple risk factors.

Topics:

Saturday, May 17, 2025

• 6:45 a.m. Registration, Breakfast & View Exhibits
• 7–7:55 a.m. Non-CME Breakfast Symposium Hosted by AstraZeneca
• 7:55 a.m. Welcome & Introductions David Cork, MD and Christopher Suhar, MD
• 8 a.m. LDL-Cholesterol: Ideal Targets. How Low is too Low? Nicholas Marston, MD
• 8:30 a.m. Non-Statin Therapies: Deep Dive Pam Taub, MD
• 9 a.m. Cardiometabolic Health: The Risk of Obesity and Pharmacotherapy Review Lauren Vincent, MD
• 9:30 a.m. Panel Discussion/Q&A
• 9:45 a.m. Break & View Exhibits
• 10:15 a.m. Resistant Hypertension Management: Current and Future Pharmacotherapies and Renal Denervation David Cork, MD
• 10:45 a.m. Diagnostic Testing for Obstructive CAD: Which Modality to Choose? Matthew Budoff, MD
• 11:15 a.m. Cardiovascular Disease in Women: An Update Martha Gulati, MD
• 11:45 a.m. Panel Discussion/Q&A
• Noon Non-CME Lunch Symposium Hosted by Novartis Pharmaceuticals Little Particle, Big Impact: Exploring Lp(a) From a Perspective of a Patient With a Premature ASCVD Event Dan Luu, PharmD, BCPS
• 1 p.m. Atrial Fibrillation Management: Introducing Pulsed Field Ablation Nicholas Olson, MD
• 1:30 p.m. Atrial Fibrillation Management: Anticoagulation or Left Atrial Appendage Occlusion? Douglas Gibson, MD
• 2 p.m. Diet and Exercise: Counsel Your Patients More Effectively Christopher Suhar, MD
• 2:30 p.m. Panel Discussion/Q&A
• 2:45 p.m. Break & View Exhibits
• 3 p.m. The Best Biomarkers to Assess Atherosclerotic Risk P. Barton Duell, MD
• 3:30 p.m. Peripheral Artery Disease Update Curtiss Stinis, MD
• 4 p.m. Diagnostic Evaluation and Management of Coronary Vasospasm and Endothelial Dysfunction Matthew Price, MD
• 4:30 p.m. Panel Discussion/Q&A
• 4:45 p.m. Adjourn Topics, times, and speakers are subject to change.